Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081372 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL1081373 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533361 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL246177 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL20726 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL23704504 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL29746410 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL626035 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL4880143 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL5560323 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274760-B2 | Method for preparing fluorine-18-labeled fluoromethyl-substituted radiopharmaceuticals using selective azide substitution reaction and precursor scavenging | BIK THERAPEUTICS INC. (KR) | 2025-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274760-B2 | Method for preparing fluorine-18-labeled fluoromethyl-substituted radiopharmaceuticals using selective azide substitution reaction and precursor scavenging | KCNK18, CYP4F8, CYP2F1 | FOLH1 2838/4885NAALAD2 3230/4885ACE 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.